VeriChip and its partner RECEPTORS LLC announced that they will launch Phase II development of an implantable glucose-sensing RFID microchip. The goal of the project is to create an alternative way for diabetes patients to monitor blood sugar without the need to draw blood.
In Phase II of the program, which is expected to be completed in the second quarter of 2010, VeriChip and RECEPTORS will focus on optimizing the glucose sensor for system stability, sensitivity and specificity.
Past attempts at creating an in vivo glucose sensor have failed due to a number of reasons, communication limitations chief among them. VeriChip believes that an RFID chip contained within a millimeter-scale selectively porous, biocompatible membrane may be the answer.
If the technology proves successful, diabetes patients will be able to read their blood sugar with the simple wave of an RFID reader.